China Resources Boya Bio-pharmaceutical Group Co.,Ltd (SHE:300294)
China · Delayed Price · Currency is CNY 18.85
+0.34 (1.84%)
At close: Mar 27, 2026
SHE:300294 Income Statement
Financials in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
Period Ending | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Operating Revenue | 2,058 | 1,734 | 2,651 | 2,761 | 2,645 |
Other Revenue | 0.99 | 0.79 | 0.85 | -2.22 | 5.21 |
| 2,059 | 1,735 | 2,652 | 2,759 | 2,651 | |
Revenue Growth (YoY) | 18.69% | -34.58% | -3.87% | 4.08% | 5.47% |
Cost of Revenue | 1,043 | 615.97 | 1,259 | 1,255 | 1,187 |
Gross Profit | 1,016 | 1,119 | 1,393 | 1,504 | 1,463 |
Selling, General & Admin | 648.36 | 603.65 | 774.85 | 923.64 | 969.52 |
Research & Development | 54.55 | 66.89 | 67.7 | 49.58 | 59.29 |
Other Operating Expenses | 18.23 | 17.47 | 18.98 | 20.83 | 19.99 |
Operating Expenses | 742.66 | 696.81 | 863.9 | 996.86 | 1,049 |
Operating Income | 272.95 | 422.12 | 529.38 | 507.16 | 414.49 |
Interest Expense | -1.16 | -0.66 | -0.46 | -0.62 | -10.53 |
Interest & Investment Income | 37.42 | 42.49 | 45.31 | 64.93 | 63.9 |
Currency Exchange Gain (Loss) | 6.61 | -2.77 | - | - | - |
Other Non Operating Income (Expenses) | -2.54 | 0.87 | -0.43 | 4.02 | -8.3 |
EBT Excluding Unusual Items | 313.28 | 462.05 | 573.81 | 575.49 | 459.57 |
Impairment of Goodwill | -110.47 | -72.61 | -298.41 | - | - |
Gain (Loss) on Sale of Investments | 59.98 | 65.58 | 85.74 | - | 10.71 |
Gain (Loss) on Sale of Assets | 5.1 | -0.61 | 1.3 | 0.07 | -0.87 |
Asset Writedown | -199.11 | -11.18 | -28.31 | -51.03 | -36.37 |
Other Unusual Items | 35.1 | 34.49 | 19.59 | 7.47 | 10.08 |
Pretax Income | 103.88 | 477.71 | 353.71 | 532 | 443.12 |
Income Tax Expense | -8.76 | 81.19 | 105.56 | 86.51 | 84.84 |
Earnings From Continuing Operations | 112.64 | 396.53 | 248.15 | 445.49 | 358.28 |
Minority Interest in Earnings | 0.06 | 0.46 | -10.68 | -13.29 | -13.75 |
Net Income | 112.7 | 396.99 | 237.47 | 432.2 | 344.53 |
Net Income to Common | 112.7 | 396.99 | 237.47 | 432.2 | 344.53 |
Net Income Growth | -71.61% | 67.18% | -45.06% | 25.45% | 32.48% |
Shares Outstanding (Basic) | 512 | 503 | 505 | 503 | 436 |
Shares Outstanding (Diluted) | 512 | 503 | 505 | 503 | 436 |
Shares Change (YoY) | 1.94% | -0.54% | 0.53% | 15.24% | 2.30% |
EPS (Basic) | 0.22 | 0.79 | 0.47 | 0.86 | 0.79 |
EPS (Diluted) | 0.22 | 0.79 | 0.47 | 0.86 | 0.79 |
EPS Growth | -72.15% | 68.08% | -45.35% | 8.86% | 29.51% |
Free Cash Flow | -474.15 | 101.99 | 554.23 | 458.03 | 1,277 |
Free Cash Flow Per Share | -0.93 | 0.20 | 1.10 | 0.91 | 2.93 |
Dividend Per Share | 0.223 | 0.320 | 0.300 | 0.200 | 0.150 |
Dividend Growth | -30.31% | 6.67% | 50.00% | 33.33% | 130.77% |
Gross Margin | 49.32% | 64.50% | 52.54% | 54.52% | 55.21% |
Operating Margin | 13.26% | 24.33% | 19.96% | 18.38% | 15.64% |
Profit Margin | 5.47% | 22.88% | 8.95% | 15.67% | 13.00% |
Free Cash Flow Margin | -23.03% | 5.88% | 20.90% | 16.60% | 48.19% |
EBITDA | 415.82 | 521.95 | 624.38 | 600.38 | 510.65 |
EBITDA Margin | 20.19% | 30.09% | 23.54% | 21.76% | 19.27% |
D&A For EBITDA | 142.87 | 99.82 | 94.99 | 93.22 | 96.16 |
EBIT | 272.95 | 422.12 | 529.38 | 507.16 | 414.49 |
EBIT Margin | 13.26% | 24.33% | 19.96% | 18.38% | 15.64% |
Effective Tax Rate | - | 16.99% | 29.84% | 16.26% | 19.15% |
Revenue as Reported | 2,059 | 1,735 | 2,652 | 2,759 | 2,651 |
Advertising Expenses | 4.55 | 3.26 | 2.73 | 1.82 | 2.5 |
Updated Dec 31, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.